Related Experiment Video
Updated: Jun 26, 2026

Enrichment of Bruch's Membrane from Human Donor Eyes
Published on: November 15, 2015
Complement factor H gene polymorphisms and Chlamydia pneumoniae infection in age-related macular degeneration
P Haas1, K Steindl, K E Schmid-Kubista
1Department of Ophthalmology, Rudolf Foundation Clinic, Ludwig Boltzmann Institute for Retinology and Biomicroscopic Lasersurgery, Vienna, Austria. paulina.haas@wienkav.at
Insights
The complement factor H (CFH) Y402H polymorphism is a significant risk factor for age-related macular degeneration (AMD) in the Austrian population. No link was found between Chlamydia pneumoniae infection and AMD or the CFH polymorphism.
Area of Science:
- Ophthalmology
- Genetics
- Infectious Diseases
Background:
- Age-related macular degeneration (AMD) is a leading cause of vision loss in older adults.
- The complement factor H (CFH) gene, specifically the Y402H polymorphism, has been implicated as a risk factor for AMD.
- Chlamydia pneumoniae infection has been hypothesized to play a role in AMD pathogenesis.
Purpose of the Study:
- To investigate the association between the CFH Y402H polymorphism and AMD in an Austrian population.
- To determine if Chlamydia pneumoniae exposure is associated with AMD or the CFH Y402H risk polymorphism.
Main Methods:
- Genotyping for the CFH Y402H polymorphism using polymerase chain reaction-restriction fragment length polymorphism analysis.
- Serological testing for Chlamydia pneumoniae IgG antibodies via ELISA.
- Statistical analysis using chi-squared tests and logistic regression to assess associations.
Main Results:
- Significant differences in CFH Y402H genotype frequencies were observed between AMD patients and healthy controls (P < 0.005).
- The odds ratio for AMD associated with the CFH Y402H polymorphism was 2.920/3.811.
- No statistically significant association was found between Chlamydia pneumoniae seropositivity and AMD (P=0.192) or the CFH Y402H polymorphism.
Conclusions:
- The CFH Y402H polymorphism is confirmed as a risk factor for AMD in the Austrian population.
- A higher frequency of the Y402H polymorphism was observed in AMD patients compared to controls.
- No association between prior Chlamydia pneumoniae infection and diagnosed AMD was identified in this study.
Purpose:
To investigate the association of the complement factor H gene (CFH)Y402H polymorphism and age-related macular degeneration (AMD) in the Austrian population (Caucasoid descent), and to determine whether there is an association between exposure to Chlamydia pneumoniae-responsible for up to 20% of community-acquired pneumoniae-and the AMD-associated CFHrisk polymorphism.
Methods:
Genotypes were determined by polymerase chain reaction-restriction fragment length polymorphism analysis in 75 unrelated AMD patients and compared with 75 healthy, age-matched control subjects. C. pneumoniaeserum IgG was tested by ELISA (R&D) in both groups. The association between the CFHY402H genetic polymorphism and the disease was examined by chi (2)-test and logistic regression.
Results:
CFH Y402H genotypefrequencies differed significantly between AMD patients and healthy controls (1277 TT, 22.7%; 1277 TC, 53.3%; and 1277 CC, 22.7% in the AMD group; 1277 TT, 48.0%; 1277 TC, 38.7%; and 1277 CC, 13.3% in the control group) showing a P-value <0.005 (OR:2.920/3.811).No association was found between a positive C. pneumoniae titre and AMD (P=0.192), nor was any association found between C. pneumoniae and the CFH Y402H polymorphism.
Conclusions:
Our data confirm that the CFHY402H polymorphism is a risk factor for AMD in the Austrian population with a higher frequency of the Y402 polymorphism in AMD patients. No association between preceding C. pneumoniaeinfection and diagnosed AMD was found.
More Related Videos
09:37A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
Published on: July 14, 2016
07:26High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
Published on: July 18, 2017
Related Concept Videos
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Cytomegalovirus Disease